Influvac - vaccine for the prevention of influenza.
Release form and composition
Influvac is produced in the form of a suspension for subcutaneous and intramuscular administration (colorless transparent liquid), 0.5 ml in single-use syringes complete with injection needles, in 1 or 10 sets in carton packs.
The composition of 1 dose (0.5 ml) includes active substances - hemagglutinin (HA) and neuraminidase (NA) of the following viral strains:
- A (H1N1) - 15 µg HA;
- A (H3N2) - 15 µg HA;
- B - 15 µg of HA.
Auxiliary components included in the preparation: sodium phosphate dihydrate, potassium chloride, potassium dihydrophosphate, magnesium chloride hexahydrate, sodium chloride, calcium chloride dihydrate, water for injection
Indications for use
Influvac prescribed for the prevention of influenza in adults and children over 6 months.
Vaccination is recommended for all individuals. This is especially true for the category of population that is at increased risk when influenza is combined with existing conditions / diseases. This category includes:
- Patients with respiratory diseases, chronic renal failure, cardiovascular diseases of any etiology, diabetes mellitus, immunodeficiency states (malignant blood diseases, HIV infection, etc.);
- Patients receiving high doses of corticosteroids, cytostatics, immunosuppressants, or radiation therapy;
- Children and adolescents (from 6 months to 18 years) who receive drugs with a content of acetylsalicylic acid for a long time, and, therefore, are at increased risk of Reye's syndrome due to influenza infection;
- Older people (over 65), regardless of their state of health;
- Pregnant women in the II-III trimester. Pregnant women in high-risk categories should be vaccinated regardless of the stage of pregnancy.
Contraindications to the use of Influvac are:
- Severe allergic or temperature reactions after previous use of subunit influenza vaccines;
- The presence of hypersensitivity to chicken protein or to any other component of the vaccine.
Vaccination should be postponed until the end of acute and exacerbation of chronic diseases. In cases of mild acute respiratory viral infections, acute intestinal and other diseases, Influvac can be used immediately after normalization of body temperature.
Dosing and Administration
Influvac administered intramuscularly or deeply subcutaneously, intravenous administration is strictly prohibited.
Immunization is carried out annually in the autumn period, in the following dosage:
- Adults and teenagers from 14 years old - 0.5 ml;
- Children from 6 months to 3 years old - at 0.25 ml;
- Children 3-14 years old - 0.5 ml.
Usually the drug is used once. Patients with immunodeficiency and when vaccinating children who have not previously had the flu and have not been vaccinated, use Influvac twice with an interval of 4 weeks.
With the use of Influvac, the development of disorders on the part of some body systems is possible:
- Immune system: rarely - allergic reactions; very rarely - anaphylactic shock;
- Lymphatic and circulatory systems: rarely - thrombocytopenia;
- Nervous system: often - headache; rarely - neuritis, convulsions, paresthesias, encephalomyelitis, Guillain-Barré syndrome.
The convincing link between these reactions and vaccination has not been established.
In the room where they are vaccinated, you need to have drugs for the treatment of anaphylactic shock (glucocorticoids, adrenaline, etc.).
There have been cases of other side effects:
- General disorders: often - neuralgia and fatigue, which do not require additional treatment and go through 1-2 days;
- Vascular system: very rarely - vasculitis with transient renal dysfunction;
- Systemic reactions: malaise, fever, sweating, tremors, pain in joints and muscles;
- Local reactions: induration, swelling, tenderness, redness, ecchymosis.
Influvac may contain an undetectable residual amount of gentamicin, so when using it, people with hypersensitivity to aminoglycosides should be careful.
The vaccine retains its properties for 1 year. The expiry date is considered to be June 30 following the year of release.
The vaccine should be warmed to room temperature before administration.
Influvac can be used in conjunction with other vaccines that need to be injected with different syringes in different parts of the body. With simultaneous use may increase side effects.
If the patient receives immunosuppressive therapy, the immune response from the use of Influvac may be reduced.
After vaccination, false-positive results of serological tests can be obtained (during ELISA - enzyme immunoassay), which after vaccination is caused by the production of IgM.
Cases of incompatibility are unknown.
Terms and conditions of storage
Store in a dark, out of reach of children at a temperature of 2-8 ° C. Do not freeze.
Shelf life - 12 months.